D-0316 First Time in Patients Ascending Dose Study
NCT03452150
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
84
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Non Small Cell Lung Cancer
Interventions
DRUG:
D-0316
Sponsor
InventisBio Co., Ltd